Germany-based Earlybird Health announced the final closing of its second fund of €173 million (around $185 million). This is more than twice the size of Earlybird's first healthcare-focused fund.
Earlybird Health, a unit of Berlin-based VC firm Earlybird Venture Capital, announced that it has closed its latest healthcare fund at €173M. According to
This is KRP203’s second Orphan Drug Designation and it is the only S1P receptor modulator being developed as an adjunctive and maintenance treatment for blood cancers.
Priothera – US FDA grants Orphan Drug Designation to mocravimod to improve the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with hematologic malignancies